CD274 and non-small cell lung carcinoma: Prevalence of positive PD-L1 expression (≥ 1%) in early-stage NSCLC patients in our study was 20.5% (SP263 Ab) and 17.5% (22C3 Ab) which was lower prevalence compared to metastatic NSCLC patients in real world data from multicenter in USA, Canada, Spain, Russia, Denmark, Argentina, Columbia, Japan, and Hong Kong (52%) [35].